| Index LDL-C (mg/dL) | Clinical ASCVD Only | HeFH Only | Clinical ASCVD and HeFH | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alla | <70 | 70-99 | 100-129 | ≥ 130 | Alla | < 70 | 70-99 | 100-129 | ≥ 130 | Alla | < 70 | 70-99 | 100-129 | ≥ 130 | |
| Number of patients | 124,279 | 35,871 | 49,389 | 24,889 | 13,952 | 666 | 20 | 33 | 74 | 534 | 385 | 56 | 44 | 41 | 244 |
| Characteristics | |||||||||||||||
| Mean age, years (SD) | 70.21 (9.86) | 70.81 (9.65) | 70.62 (9.66) | 69.56 (9.99) | 68.40 (10.56) | 60.00 (13.8) | 61.30 (11.1) | 63.12 (9.9) | 62.89 (13.2) | 59.38 (14.1) | 65.49 (10.59) | 64.23 (9.43) | 65.82 (9.77) | 68.27 (9.04) | 65.25 (11.18) |
| Female, % | 51.5 | 42.4 | 51.0 | 58.1 | 65.1 | 72.2 | 55.0 | 69.7 | 63.5 | 74.3 | 67.0 | 48.2 | 68.1 | 51.2 | 73.7 |
| Diabetes, % | 59.0 | 66.7 | 57.7 | 54.0 | 52.9 | 36.6 | 75.7 | 54.5 | 40.5 | 33.3 | 65.5 | 94.6 | 79.5 | 65.9 | 56.1 |
| LDL-C, mean (SD) | 89.68 (31.41) | 58.77 (17.10) | 85.84 (13.51) | 110.93 (14.69) | 144.76 (25.19) | 224.73 (61.71) | 144.45 (62.41) | 150.33 (39.99) | 155.92 (34.42) | 241.76 (53.03) | 196.23 (86.94) | 94.95 (58.93) | 138.87 (39.12) | 148.73 (42.15) | 237.81 (74.29) |
| CCI, mean (SD) | 1.99 (1.89) | 2.19 (1.96) | 1.95 (1.87) | 1.86 (1.85) | 1.85 (1.83) | 0.94 (1.46) | 1.60 (1.88) | 1.24 (1.37) | 1.28 (1.79) | 0.86 (1.39) | 2.19 (1.97) | 2.70 (2.19) | 1.98 (1.73) | 2.44 (2.50) | 2.08 (1.84) |
| Race or ethnicity, % | |||||||||||||||
| Asian | 6.1 | 6.9 | 5.4 | 6.0 | 6.7 | 8.5 | 0.0 | 8.3 | 14.8 | 8.0 | 5.8 | 0 | 10.3 | 12.1 | 5.7 |
| Black | 21.9 | 19.7 | 21.5 | 23.2 | 26.4 | 21.6 | 0.0 | 16.7 | 18.5 | 23.3 | 22.5 | 9.1 | 3.4 | 36.4 | 27.8 |
| Caucasian | 52.1 | 57.5 | 54.3 | 47.3 | 41.0 | 43.2 | 78.5 | 54.2 | 50.0 | 40.1 | 55.3 | 85.5 | 79.3 | 39.4 | 43.7 |
| Hispanic | 14.5 | 10.1 | 13.5 | 18.5 | 20.9 | 12.6 | 7.1 | 12.5 | 5.6 | 13.9 | 12.4 | 5.5 | 3.4 | 9.1 | 17.1 |
| Other | 5.4 | 5.8 | 5.4 | 5.0 | 5.0 | 14.0 | 14.3 | 8.3 | 11.1 | 14.7 | 4.0 | 0 | 3.4 | 3.0 | 5.7 |
| Geographic region, % | |||||||||||||||
| Midwest | 10.5 | 11.6 | 11.1 | 9.3 | 7.2 | 10.1 | 10.0 | 3.0 | 4.1 | 11.2 | 5.7 | 0.0 | 4.5 | 9.8 | 6.6 |
| Northeast | 41.8 | 43.1 | 41.1 | 40.7 | 43.5 | 41.1 | 20.0 | 48.5 | 44.6 | 40.8 | 35.1 | 8.9 | 20.4 | 51.2 | 41.0 |
| South | 39.7 | 37.1 | 39.6 | 42.4 | 42.0 | 40.4 | 60.0 | 33.3 | 43.2 | 39.9 | 52.5 | 89.3 | 65.9 | 39.0 | 43.9 |
| West | 8.0 | 8.2 | 8.2 | 7.6 | 7.3 | 8.4 | 10.0 | 15.2 | 8.1 | 8.1 | 6.8 | 1.8 | 9.1 | 0 | 8.6 |
| Payer type, % | |||||||||||||||
| Commercial | 11.1 | 11.2 | 11.1 | 11.0 | 10.4 | 31.7 | 10.0 | 18.2 | 27.0 | 33.9 | 9.9 | 1.8 | 9.1 | 2.4 | 13.1 |
| Medicaid | 5.8 | 4.5 | 4.9 | 6.8 | 9.9 | 14.7 | 10.0 | 21.2 | 8.1 | 15.4 | 9.3 | 0 | 2.27 | 4.9 | 13.5 |
| Medicare | 83.0 | 84.0 | 83.9 | 82.0 | 79.6 | 53.5 | 80.0 | 60.6 | 64.9 | 50.6 | 80.8 | 98.2 | 88.6 | 92.7 | 73.4 |
| Other | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0 | 0 | 0 | 0.2 | 0 | 0 | 0 | 0 | 0 |
| Clinical ASCVD, % | |||||||||||||||
| ACS | 8.6 | 9.8 | 8.4 | 7.7 | 7.9 | 0 | 0 | 0 | 0 | 0 | 6.8 | 3.6 | 9.1 | 12.2 | 6.1 |
| History of MI | 27.0 | 31.5 | 27.0 | 23.3 | 21.7 | 0 | 0 | 0 | 0 | 0 | 41.0 | 82.1 | 52.3 | 46.3 | 28.7 |
| Angina | 15.9 | 16.5 | 15.8 | 15.5 | 15.7 | 0 | 0 | 0 | 0 | 0 | 15.8 | 3.6 | 15.9 | 14.6 | 18.9 |
| PAD | 53.3 | 53.6 | 53.4 | 53.2 | 52.4 | 0 | 0 | 0 | 0 | 0 | 45.2 | 32.1 | 45.5 | 36.6 | 49.6 |
| IS | 9.6 | 10.3 | 9.3 | 9.4 | 9.7 | 0 | 0 | 0 | 0 | 0 | 10.9 | 7.1 | 6.8 | 19.5 | 11.1 |
| IS/TIA | 10.8 | 11.0 | 10.6 | 10.9 | 11.2 | 0 | 0 | 0 | 0 | 0 | 12.5 | 10.7 | 11.4 | 14.6 | 12.7 |
| TIA | 8.6 | 8.2 | 8.5 | 8.9 | 9.3 | 0 | 0 | 0 | 0 | 0 | 9.9 | 7.1 | 6.8 | 12.2 | 10.7 |
| Pre-index (60 days) statin intensity, % | |||||||||||||||
| Low/medium | 35.1 | 31.6 | 38.2 | 39.2 | 26.5 | 25.8 | 35.0 | 27.2 | 21.6 | 26.0 | 20.5 | 48.2 | 18.2 | 24.4 | 13.9 |
| High | 35.6 | 45.3 | 36.5 | 27.4 | 22.0 | 51.2 | 55.0 | 63.6 | 56.8 | 49.4 | 38.2 | 41.1 | 59.1 | 53.7 | 31.1 |
| Combination | 0.3 | 0.4 | 0.3 | 0.2 | 0.2 | 0.9 | 0 | 0 | 0 | 1.1 | 0.3 | 0.0 | 2.3 | 0.0 | 0.0 |
| Outcomes | |||||||||||||||
| Add ezetimibe to statins | 1,132 (3.2) | 263 (0.7) | 313 (0.9) | 285 (0.8) | 271 (0.8) | 21 (3.2) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 20 (3.7) | 17 (4.4) | 0 (0.0) | 2 (4.5) | 1 (2.4) | 14 (5.7) |
| Achieved < 70 mg/dL | 28.3 | 62.4 | 29.4 | 15.1 | 7.7 | 4.8 | 0 | 0 | 0 | 5.0 | 5.9 | 0 | 50.0 | 0 | 0 |
| Did not achieve < 70 mg/dL | 57.5 | 25.5 | 55.6 | 71.2 | 76.4 | 81.0 | 100.0 | 0 | 0 | 80.0 | 82.4 | 0 | 50.0 | 100.0 | 85.7 |
| Switch to ezetimibe | 132 (0.4) | 14 (0.0) | 27 (0.1) | 32 (0.1) | 59 (0.2) | 3 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (0.6) | 4 (1.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (1.6) |
| Achieved < 70 mg/dL | 15.2 | 42.9 | 33.3 | 6.3 | 5.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did not achieve < 70 mg/dL | 71.2 | 35.7 | 51.9 | 87.5 | 79.7 | 66.7 | 0 | 0 | 0 | 66.7 | 25.0 | 0 | 0 | 0 | 25.0 |
Data source: Inovalon MORE2 Registry.
aThis category may include patients whose values are non-numerical and therefore not contained in the stratified LDL-C categories.
ACS = acute coronary syndrome; ASCVD = atherosclerotic cardiovascular disease; CCI = Charlson Comorbidity Index; HeFH = heterozygous familial hypercholesterolemia; IS = ischemic stroke; LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; PAD = peripheral artery disease; SD = standard deviation; TIA = transient ischemic attack.